Showing results (171-180 of 1,688) with videos related to
Sort By:
Pageof 169
Plos One|May 9, 2018
Cancer driver mutation prediction through Bayesian integration of multi-omic dataZixing Wang, Kwok-Shing Ng, Tenghui Chen, et al.NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.Annals of Surgical Oncology|January 18, 2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast CancerKelly K Hunt, Vera J Suman, Hannah F Wingate, et al.Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.Journal of the American College of Surgeons|November 6, 2012
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient populationMin Yi, Henry M Kuerer, Elizabeth A Mittendorf, et al.Journal of Hepatology|March 30, 2026
Global patterns of mutational profiles in biliary tract cancerYan Zhu, Jason A Wu, Dengyong Zhang, et al.Immunotherapy|July 20, 2010
New trends in epidermal growth factor receptor-directed monoclonal antibodiesBen Markman, Jaume Capdevila, Elena Elez, et al.Gastrointestinal Cancer Research : GCR|December 17, 2009
Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancerRichard M Goldberg, Neal J Meropol, Josep TaberneroAnnals of Surgical Oncology|March 13, 2009
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservationJudy C Boughey, Jamie Wagner, Betsy J Garrett, et al.Radiation Oncology (London, England)|January 15, 2013
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomyHeath D Skinner, Eric A Strom, Sabin B Motwani, et al.Pageof 169